STOCK TITAN
  1. Home
  2. News
  3. THAR

Tharimmune, Inc. - THAR STOCK NEWS

Welcome to our dedicated page for Tharimmune news (Ticker: THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.

Tharimmune, Inc., trading under the symbol THAR on NASDAQ, is a clinical-stage biotechnology company dedicated to developing therapeutic solutions for rare immune, inflammatory, and oncologic diseases. The company's primary focus is the advancement of its portfolio of therapeutic candidates, with a notable asset, TH104, aimed at treating chronic, debilitating pruritus in primary biliary cholangitis (PBC), a rare and orphan liver disease with no known cure.

Tharimmune is actively engaged in the development of novel multi-specific antibodies targeting unique epitopes in multiple solid tumors. These antibodies employ new mechanisms of action against validated targets, offering innovative solutions in the field of immuno-oncology. A key collaboration with OmniAb, Inc. allows Tharimmune to leverage advanced antibody discovery technology for these specified targets.

The company recently announced the pricing of an underwritten public offering, raising $10 million to fund its ongoing phase 2 trial for TH104, expected in 2024, and other general corporate purposes. This financial boost will support their clinical and non-clinical programs, ensuring sustained progress towards their mission.

In its latest Phase 1 trial conducted in India, TH104 demonstrated a significant reduction in pruritus among patients with chronic liver disease, with a 33.3% decrease in 24-hour mean itching intensity score. The trial also confirmed the safety of TH104, showing no unexpected treatment-emergent adverse events. These promising results lay the groundwork for an upcoming Phase 2a trial in the US, anticipated to yield pivotal data in 2024.

Tharimmune has consistently demonstrated a commitment to scientific excellence and patient care. Their ongoing research is poised to make significant contributions to the treatment of liver-related and other pruritogenic inflammatory conditions, as well as novel therapies for cancer treatment. With a strong pipeline and strategic partnerships, Tharimmune is well-positioned to lead advancements in biotechnology.

News

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Rhea-AI Summary
Tharimmune, a clinical-stage biotechnology company, announced an option agreement with Washington University to develop HER2/HER3 antibody drug conjugates. The technology focuses on human HER2 antibodies, complementing Tharimmune's pipeline of novel antibodies. Prof. Schreiber from Washington University highlighted the importance of targeting HER2, a well-studied tumor marker. Tharimmune aims to develop antibodies targeting HER2 and HER3, potentially creating innovative combination therapies. The agreement enhances Tharimmune's early-stage pipeline by incorporating cutting-edge technology from Washington University, known for its expertise in medicine and biomedical research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
-
News

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Rhea-AI Summary
Tharimmune forms a Scientific Advisory Board to drive clinical-stage lead in chronic liver disease and early-stage tunable Knob domains for generating Antibody Drug Conjugate (ADC) Biotherapeutics. The board includes experts in immunology, liver diseases, protein engineering, and ADCs to advance therapeutic candidates in inflammation & immunology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
management
-
News

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Rhea-AI Summary
Tharimmune, a clinical-stage biotechnology company (NASDAQ: THAR), is set to present at the Emerging Growth Conference on March 7, 2024. The presentation by Chairman and CEO Randy Milby will provide insights into the company's therapeutic candidates in inflammation & immunology. Investors and analysts can engage with the management team in real-time during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
News

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Rhea-AI Summary
Tharimmune, Inc. (NASDAQ:THAR) announces successful completion of Phase 1 clinical trial for TH104, a transmucosal buccal film for liver-related conditions. Positive safety and tolerability profile demonstrated, with mild side effects. Phase 2 study for chronic pruritus in PBC on-track for 2024 initiation. Company well-funded till 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
clinical trial
-
News

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Rhea-AI Summary
Tharimmune, Inc. (NASDAQ:THAR) has completed dosing the first patient in the Phase 1 clinical trial of TH104, a proprietary transmucosal buccal film designed for liver-related and pruritogenic inflammatory conditions. The trial aims to assess safety, tolerability, and absolute bioavailability of TH104, with topline data expected in 2Q24. The company is fully funded until 2025 and anticipates full readouts of Phase 1 and 2 in moderate-to-severe chronic pruritus in PBC in 4Q24/1Q25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
clinical trial
-
News

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Rhea-AI Summary
Tharimmune, Inc. (NASDAQ:THAR) announces Phase 1 trial initiation for TH104, a potential treatment for liver-related and pruritogenic inflammatory conditions. The company plans to engage in Phase 2 trials for moderate-to-severe chronic pruritus in PBC patients and outlines a near-clinical pipeline for immuno-oncology targets. Tharimmune is fully funded into 2025 with Phase 1 and Phase 2 results expected in 4Q24/1Q25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
clinical trial
News

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Rhea-AI Summary
Tharimmune, Inc. (Nasdaq: THAR) announced positive phase 1 data for TH104, showing a 33.3% decrease in 24-hour mean itching intensity score after a single dose. The company is well-funded into early 2025 and expects bridging PK data in the US and Phase 2a results for chronic pruritus in primary biliary cholangitis (PBC) in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
-
News

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Rhea-AI Summary
Tharimmune, Inc. (Nasdaq:THAR) closed a public offering of 11,000,000 shares of common stock, raising approximately $11 million. The net proceeds will be used for the advancement of TH104's phase 2 trial expected in 2024, working capital, and other general corporate purposes. ThinkEquity acted as the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.19%
Tags
offering
-
News

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Rhea-AI Summary
Tharimmune, a clinical-stage biotechnology company (NASDAQ:THAR), announced the pricing of an underwritten public offering of 10,000,000 shares of common stock at a public offering price of $1.00 per share, resulting in gross proceeds of $10,000,000. The company intends to use the net proceeds for the advancement of TH104's phase 2 trial expected in 2024, as well as for working capital and other general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-72.36%
Tags
offering
News

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Rhea-AI Summary
Tharimmune, Inc. (NASDAQ:THAR) announced positive phase 1 data with TH104, a buccal film for chronic pruritis in primary biliary cholangitis (PBC) patients. The company expects to engage FDA on Phase 2 trial design and expects topline data in 2024. The phase 1 trial achieved predictable pharmacokinetic profiling with favorable safety and tolerability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.09%
Tags
clinical trial

FAQ

What is the current stock price of Tharimmune (THAR)?

The current stock price of Tharimmune (THAR) is $2.09 as of December 23, 2024.

What is the market cap of Tharimmune (THAR)?

The market cap of Tharimmune (THAR) is approximately 3.1M.

What is Tharimmune, Inc.'s primary focus?

Tharimmune, Inc. focuses on developing therapeutic candidates for rare immune, inflammatory, and oncologic diseases, with key assets aimed at treating conditions like chronic pruritus in primary biliary cholangitis (PBC).

What is TH104?

TH104 is a clinical-stage asset developed by Tharimmune intended to treat chronic, debilitating pruritus in primary biliary cholangitis (PBC), a rare liver disease.

How did Tharimmune perform in its recent Phase 1 trial for TH104?

The recent Phase 1 trial for TH104 showed a 33.3% reduction in 24-hour mean itching intensity in patients with chronic liver disease, confirming the safety and efficacy of the product.

What are Tharimmune's plans for TH104 moving forward?

Tharimmune plans to initiate a Phase 2a trial in the United States in 2024 to further evaluate the efficacy of TH104 in treating pruritus in PBC patients.

How much did Tharimmune raise in its recent public offering?

Tharimmune raised $10 million in its recent underwritten public offering to fund clinical trials and general corporate purposes.

What partnerships does Tharimmune have?

Tharimmune has a key partnership with OmniAb, Inc. to access advanced antibody discovery technology platforms to develop their therapeutic candidates.

What are the primary results from the Phase 1 trial of TH104?

The Phase 1 trial indicated a 33.3% decrease in pruritus, with TH104 being well tolerated without unexpected adverse events, highlighting its potential in treating chronic liver disease-related pruritus.

What other projects are Tharimmune working on?

In addition to TH104, Tharimmune is developing multi-specific antibodies targeting unique epitopes in various solid tumors through its early-stage immuno-oncology pipeline.

How is Tharimmune funded for its upcoming projects?

Tharimmune is funded into early 2025 following a successful $10 million public offering, which supports ongoing and future clinical trials and corporate activities.

What can we expect from Tharimmune in the near future?

Tharimmune plans to release phase 1 pharmacokinetic data in 2Q24, initiate a phase 2a trial for TH104 in 2024, and continue advancing its portfolio of therapeutic candidates for rare diseases and oncology.

Stock THAR logo
Tharimmune, Inc.

Nasdaq:THAR

THAR Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

THAR Stock Data

3.06M
1.46M
1.79%
1.63%
6.44%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BRIDGEWATER